Subcutaneous Immunotherapy for Mouse in Adults

Asthma Clinical Trial

— SCITMO  

Official title:

A Biomarker-Based Pilot Study of Mouse Subcutaneous Immunotherapy in Mouse Sensitive Adults With Asthma and/or Perennial Allergic Rhinitis (ICAC-26)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02532179
• Other study ID #: DAIT ICAC-26
• Status: Completed
• Phase: Phase 1/Phase 2
• First received: August 21, 2015
• Last updated: February 5, 2018
• Start date: October 2015
• Est. completion date: October 2016

Study information

• Verified date: February 2018
• Source: National Institute of Allergy and Infectious Diseases (NIAID)
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is an open label trial of mouse allergenic extract administered by subcutaneous injection in adults with asthma and mouse sensitivity. The study is designed to evaluate:

• the safety of this therapy when given by injection

• biomarkers of the immune response and

• whether the therapy would be effective in treating allergic asthma.

Description:

The primary objective of the study is to assess if treatment with mouse subcutaneous immunotherapy (SCIT), using the per protocol allergenic extract doses, is safe. This will be done by determining the rate of related adverse events and serious adverse events in the course of treatment.

Secondary objectives include:

• determination of whether a 24 week treatment with mouse SCIT, using the per protocol allergenic extract doses, will induce a 3-fold increase in mouse-specific serum immunoglobulin E (IgE)

• determination of whether a 24 week treatment with mouse SCIT, using the per protocol allergenic extract doses, will induce changes in the serum levels of mouse-specific immunoglobulin G (IgG) and immunoglobulin subclass 4 (IgG4).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 12
• Est. completion date: October 2016
• Est. primary completion date: October 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 55 Years

Eligibility

INCLUSION CRITERIA

Participants who meet any of the following criteria are not eligible for enrollment but may be reassessed. Participants are ineligible if they:

• Are pregnant or lactating. Females must be abstinent or use a medically acceptable birth control method throughout the study (e.g. oral, subcutaneous, mechanical, or surgical contraception);

• Cannot perform spirometry at Screening;

• Have an asthma severity classification at Recruitment of severe persistent, using the NAEPP classification, as evidenced by at least one of the following:

• Requires a dose of greater than 500 mcg of fluticasone per day or the equivalent of another inhaled corticosteroid;

• Have received more than 2 courses of oral or parenteral corticosteroids within the last 12 months;

• Have been treated with depot steroids within the last 12 months;

• Have been hospitalized for asthma within the 6 months prior to recruitment;

• Have had a life-threatening asthma exacerbation that required intubation, mechanical ventilation, or that resulted in a hypoxic seizure within 2 years prior to recruitment.

• Do not have access to a phone (needed for scheduling appointments);

• Have received allergen immunotherapy (SLIT or SCIT) in the last 12 months prior to recruitment or who plan to initiate or resume allergen immunotherapy during the study;

• Have previously been treated with anti-IgE therapy within 1 year of recruitment;

• Have received an investigational drug in the 30 days prior to recruitment or who plan to use an investigational drug during the study;

• Refuses to sign the Epinephrine Auto-injector Training Form.

EXCLUSION CRITERIA

Participants who meet any of the following criteria are not eligible for enrollment and may not be reassessed. Participants are ineligible if they:

• Do not primarily speak English;

• Plan to move from the area during the study period;

• Have a history of idiopathic anaphylaxis or anaphylaxis grade 2 or higher as defined per protocol;

• Have unstable angina, significant arrhythmia, uncontrolled hypertension, history of autoimmune disease, or other chronic or immunological diseases that in the opinion of the investigator might interfere with the evaluation of the investigational agent or pose additional risk to the participant;

• Are using tricyclic antidepressants or beta-adrenergic blocker drugs (both oral and topical);

• Have not received the seasonal Flu (Influenza) Vaccine if enrolling December through March.

Related Conditions & MeSH terms

• Asthma
• Perennial Allergic Rhinitis
• Rhinitis
• Rhinitis, Allergic
• Rhinitis, Allergic, Perennial

Intervention

Biological:
• Mouse Allergenic Extract
Subjects will receive escalating doses of glycerinated mouse allergenic extract administered subcutaneously up to a maximum study dose (MSD) of 0.4 mL of extract at a concentration of 1:10 wt/vol., per protocol.

Locations

Country	Name	City	State
United States	Johns Hopkins Children's Center: Department of Allergy & Immunology	Baltimore	Maryland
United States	Ann and Robert Lurie Children's Hospital of Chicago	Chicago	Illinois
United States	Henry Ford Health System: Division of Allergy and Immunology	Detroit	Michigan
United States	Children's National Health System	Washington	District of Columbia

Sponsors (2)

Lead Sponsor	Collaborator
National Institute of Allergy and Infectious Diseases (NIAID)	Inner-City Asthma Consortium

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Reported Adverse Events (AEs)	Frequency of any AEs tabulated by preferred event term.	Baseline (Pre-Treatment) through 24 Weeks of Treatment
Primary	Number of Reported Serious Adverse Events (SAEs)	Frequency of any Serious Adverse Events (SAEs) throughout the duration of study participation.	Baseline (Pre-Treatment) through 24 Weeks of Treatment
Secondary	Change in Mouse-Specific IgE Antibodies	Serum Immunoglobulin E (IgE) is an antibody produced by the immune system. If a participant has an allergy, the immune system will respond to that particular allergen by producing IgE antibodies. These antibodies travel to cells that release chemicals, causing allergic reactions.; This endpoint/outcome is the ratio of geometric means for baseline mouse-specific serum IgE versus post-baseline mouse-specific serum IgE. The numerator is the geometric mean post-baseline IgE and the denominator is baseline IgE. A ratio of greater than 1 would indicate an increase in IgE throughout the course of the study.	Baseline (Pre-Treatment) through Week 24
Secondary	Change in Mouse-Specific IgG Antibodies	Serum Immunoglobulin G (IgG) is an antibody produced by the immune system. If a participant has bacterial or viral infections, the immune system will respond to that particular infection by producing IgG antibodies.; This endpoint/outcome is the ratio of geometric means for baseline mouse-specific serum IgG versus post-baseline mouse-specific serum IgG. The numerator is the geometric mean post-baseline IgG and, the denominator is the baseline IgG. A ratio of greater than 1 would indicate an increase in IgG throughout the course of the study.	Baseline (Pre-Treatment) to Week 24
Secondary	Change in Mouse-Specific IgG4 Antibodies	Serum Immunoglobulin G4 (IgG4) is a subtype of antibody produced by the immune system. If a participant has bacterial or viral infections, the immune system will respond to that particular infection by producing IgG4 antibodies.; This endpoint/outcome is the ratio of geometric means for baseline mouse-specific serum IgG4 versus post-baseline mouse-specific serum IgG4. The numerator is the geometric mean post-baseline IgG4 and, the denominator is the baseline IgG4. A ratio of greater than 1 would indicate an increase in IgG4 antibodies throughout the course of the study.	Baseline (Pre-Treatment) to Week 24
Secondary	Change in In-vitro Mouse Antigen Binding to B-cells	The plan was to analyze serum from cockroach subcutaneous immunotherapy (SCIT)-treated participants to determine if treatment inhibits in-vitro mouse antigen binding to B-cells after 6-months of treatment with mouse SCIT, using the per protocol allergenic extract doses. However, the Sponsor cancelled pursuit of mouse immunotherapy within its program at this time due to assay development complexities and cost; thus, there are no analyses/results for this endpoint/outcome.	Baseline (Pre-Treatment) to Week 24

External Links

•   History, project and sites of the Inner-city Asthma Consortium (ICAC)
•   Information: National Asthma Education and Prevention Program (NAEPP)
•   National Institute of Allergy and Infectious Diseases (NIAID)